TY - JOUR
T1 - Antibody therapies for the treatment of acute myeloid leukemia
T2 - exploring current and emerging therapeutic targets
AU - Morse, Joshua W.
AU - Rios, Margarita
AU - Ye, John
AU - Rios, Adan
AU - Zhang, Cheng Cheng
AU - Daver, Naval G.
AU - DiNardo, Courtney D.
AU - Zhang, Ningyan
AU - An, Zhiqiang
N1 - Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Introduction: Acute myeloid leukemia (AML) is the most common and deadly type of leukemia affecting adults. It is typically managed with rounds of non-targeted chemotherapy followed by hematopoietic stem cell transplants, but this is only possible in patients who can tolerate these harsh treatments and many are elderly and frail. With the identification of novel tumor-specific cell surface receptors, there is great conviction that targeted antibody therapies will soon become available for these patients. Areas covered: In this review, we describe the current landscape of known target receptors for monospecific and bispecific antibody-based therapeutics for AML. Here, we characterize each of the receptors and targeted antibody-based therapeutics in development, illustrating the rational design behind each therapeutic compound. We then discuss the bispecific antibodies in development and how they improve immune surveillance of AML. For each therapeutic, we also summarize the available pre-clinical and clinical data, including data from discontinued trials. Expert opinion: One antibody-based therapeutic has already been approved for AML treatment, the CD33-targeting antibody-drug conjugate, gemtuzumab ozogamicin. Many more are currently in pre-clinical and clinical studies. These antibody-based therapeutics can perform tumor-specific, elaborate cytotoxic functions and there is growing confidence they will soon lead to personalized, safe AML treatment options that induce durable remissions.
AB - Introduction: Acute myeloid leukemia (AML) is the most common and deadly type of leukemia affecting adults. It is typically managed with rounds of non-targeted chemotherapy followed by hematopoietic stem cell transplants, but this is only possible in patients who can tolerate these harsh treatments and many are elderly and frail. With the identification of novel tumor-specific cell surface receptors, there is great conviction that targeted antibody therapies will soon become available for these patients. Areas covered: In this review, we describe the current landscape of known target receptors for monospecific and bispecific antibody-based therapeutics for AML. Here, we characterize each of the receptors and targeted antibody-based therapeutics in development, illustrating the rational design behind each therapeutic compound. We then discuss the bispecific antibodies in development and how they improve immune surveillance of AML. For each therapeutic, we also summarize the available pre-clinical and clinical data, including data from discontinued trials. Expert opinion: One antibody-based therapeutic has already been approved for AML treatment, the CD33-targeting antibody-drug conjugate, gemtuzumab ozogamicin. Many more are currently in pre-clinical and clinical studies. These antibody-based therapeutics can perform tumor-specific, elaborate cytotoxic functions and there is growing confidence they will soon lead to personalized, safe AML treatment options that induce durable remissions.
KW - Acute myeloid leukemia
KW - antibody
KW - antibody-drug conjugate
KW - bispecific antibody
KW - CD33
KW - CD47
KW - fusion protein
KW - immunotherapy
KW - LILRB4
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85149303598&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149303598&partnerID=8YFLogxK
U2 - 10.1080/13543784.2023.2179482
DO - 10.1080/13543784.2023.2179482
M3 - Review article
C2 - 36762937
AN - SCOPUS:85149303598
SN - 1354-3784
VL - 32
SP - 107
EP - 125
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 2
ER -